Lopitid 200 Hasan treatments for hyperliglycerides (3 blisters x 10 tablets)

ATC code: C10AB02.

Mechanism of action

Bezafibrat is a fibrat lipid that belongs to fibrat groups. Bezafibrat reduces lipoprotein very low density and low density lipoprotein (VLDL and LDL) and increases high density lipoprotein (HDL). The activity of triglyceride lipase (lipoprotein lipase and hepatic lipoprotein lipase) is related to the metabolism of lipoprotein -rich triglycerides increased by Bezafibrat, increasing low -density hydrolytic hydrolyzi (chylomicron, VLDL), and HDL's precursors are shaped into HDL synthesis. Moreover, the synthesis of cholesterol has been reduced due to the effect of Bezafibrat accompanied by the catabolism of lipoprotein through the LDL receptor.

Studies show that Bezafibrat is effective in treating hyperlipidemia in diabetics. In some cases, it is beneficial in reducing blood sugar.

Serpting significantly decreased fibrinogen levels in serum has been observed in patients with hypercinogen blood being treated with Bezafibrat.

There is evidence that fibrat treatment may reduce coronary artery events but do not show reducing the rate of mortality in primary or secondary provisions of cardiovascular disease.

Dynamic pharmacokinetics

absorption

Bezafibrat is absorbed quickly and completely through the gastrointestinal tract. The peak concentration of plasma is about 8 mg/1, achieved after 1-2 hours orally the dose of 200 mg in healthy volunteers.

distribution

Bezafibrat binds to plasma proteins about 95%. 17 liters of distribution.

transformation

50% Bezafibrat is transferred to the kidneys in a constant form, 20% in the form of an associate with glucuronic acid.

Elimination

Bezafibrat is mainly eliminated by the kidneys. 95% of the drug excreted through the kidneys and 3% through the stool within 48 hours.

50% excreted in the form of drugs unchanged and 20% in an associated with glucuronic acid.

The renal clearance is 3.4 - 6 v/h, the sale time is about 1-2 hours.

pharmacokinetics in special subjects:

In the elderly, the elimination process may be changed in people with impaired liver function. Patients with liver disease (except fatty liver) contraindicated to Bezafibrat.

In older patients with impaired renal function by age, the dozafibrat dose should be adjusted according to serum creatinine and creatinine clearance.

The reduction of bezafibrat dose in patients with renal function is necessary to prevent the accumulation of drugs and unwanted effects.

Due to strong bonds to plasma proteins, Bezafibroat is not appraised during dialysis (Cuprophan filter), contraindicated bezafibrate with patients being dialysis.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?

overdose

There are no specific symptoms of the overdose recorded. There may be pattern.

How to deal with overdose

There is no specific antidote, appropriate symptomatic treatment is recommended in case of overdose. In the case of pattern, must stop using Bezafibrat and monitor kidney function.

In case of emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when forgetting a dose? However, if close to the next dose, skip that dose, do not use double the dose to compensate for the forgotten dose.

need to be very careful when taking the drug for patients in the following cases:

Bezafibrat should be used after the patient does not respond to a diet, other measures such as physical activity, weight loss and full treatment of other metabolic disorders.

Secondary cause of blood lipid disorders such as type 2 diabetes is not controlled, hypothyroidism, kidney syndrome, blood protein disorders, obstructive liver disease, drug treatment, alcoholism should be fully treated before starting bezafibrate treatment.

Bezafibrate and other fibrats can cause muscle disease, muscle weakness or muscle pain, often accompanied by a significant increase in Creatin Kinase (CPK).

In some cases, serious muscle lesions (muscle pepper) have been observed. The risk of muscle pattern can increase when overdose Bezafibrat, the most common in patients with impaired renal function and in patients with risk factors for muscle disease (including renal failure, the elderly (> 65 years), patients with genetic properties of muscle disorders and history of muscle toxicity with fibrat drugs or other lipid medications, hypothyroidism, severe infections, oral disorders, oral disorders, oral disorders, oral disorders, oral infection lots of alcohol).

Bezafibrat should be used cautiously when combined with HMG inhibitors of Coa Reductase because of the risk of increasing the rate and severity of muscle disease. Patients need to be notified of symptoms and monitoring of CPK's signs of muscle disease and coordinating therapy if there are signs of muscle disease. Do not use combination therapy in patients with risk factors for muscle disease.

Bezafibrat changes the composition of the bile. There have been reports on the development of gallstones.

Bezafibrate can cause gallstones, need to take appropriate diagnostic measures if there are signs or obstruction symptoms.

Estrogen may increase blood lipid content, need to be cautious when prescribing Bezafibrat in patients using estrogen or contraceptives containing estrogen.

When using Bezafibrat in combination with anion exchange resin (eg Colestyramin), two drugs must be taken at least 2 hours apart.

The effect of the drug on driving and operating machinery

Bezafibrat has been shown to cause dizziness and may have light to medium impact for driving or using machinery.

Patients should not drive or use machines if affected.

Using drugs for women during pregnancy and lactation

Using drugs for pregnant women

There are very little data on the use of BezafiboBibrat in pregnant women. Animal studies are incomplete about reproductive toxicity, potential risks for humans are unknown. Bezafibrat is not recommended during pregnancy and in women who are likely to not use contraception.

Using medicine for breastfeeding women

There is no enough information about the excretion of Bezafibrat or its metabolic substance in breast milk, but the risk for breastfed babies cannot be excluded. It is necessary to consider choosing between stopping breast milk or stopping the use of Bezafibrat taking into account the benefits of breastfeeding and the benefits of the mother's treatment.

Medicinal interaction

should be cautious when taking Bezafibrat for patients who are taking Coumarin anticoagulants because they can increase the effects of anticoagulants. The anticoagulant dose needs to be reduced by 50% and then adjust the dose by regularly checking blood clotting.

Bezafibrat increases the effects of diabetes treatment including insulin.

If it is necessary to use it simultaneously with an ion exchange resin, it is necessary to use at least 2 hours apart, because the ion exchange resin can reduce the absorption of Bezafibrat.

In special cases, there is a decline in renal function (accompanied by an increase in the corresponding serum creatinine level) which has been reported in the organs with organs that are treated with immunosuppressive therapy along with Bezafibrat, renal function should be closely monitored in these patients and stop using Bezafibrat if necessary.

ENZYMY ACCIES (POLICY POLICY IT) Should not be used simultaneously with Bezafibrat.

The interaction between HMG inhibitors and Fibrat can differ in nature and intensity depending on the combination of the drugs used. Pharmacological interaction between these two drugs can occur and in some cases these interactions also contribute to the increased risk of muscle disease.

The similarity of the drug

Due to the absence of studies on the correlation of the drug, not mixing this drug with other drugs.